Patents by Inventor Jennifer Dumont

Jennifer Dumont has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 9241978
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: March 11, 2013
    Date of Patent: January 26, 2016
    Assignee: BIOGEN HEMOPHILIA INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • CELL LINE EXPRESSING SINGLE CHAIN FACTOR VIII POLYPEPTIDES AND USES THEREOF
    Publication number: 20150191526
    Abstract: The present invention provides cell lines for producing single chain FVIII polypeptides, e.g., chimeric single chain FVIII polypeptides, methods of producing single chain FVIII polypeptides, single chain FVIII polypeptides, and methods of treating Hemophilia A with a single chain Factor VIII polypeptide.
    Type: Application
    Filed: July 5, 2013
    Publication date: July 9, 2015
    Applicant: Biogen Idec MA Inc.
    Inventors: Susan Low, Jennifer A. Dumont, Alan J. Bitonti
  • Factor VIII-Fc chimeric and hybrid polypeptides, and methods of use thereof
    Patent number: 9050318
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Grant
    Filed: December 6, 2010
    Date of Patent: June 9, 2015
    Assignee: Biogen Idec Hemophilia Inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FACTOR VIII CHIMERIC AND HYBRID POLYPEPTIDES, AND METHODS OF USE THEREOF
    Publication number: 20140294821
    Abstract: The present invention provides methods of administering Factor VIII (processed FVIII, single chain FVIII, or a combination thereof); methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells
    Type: Application
    Filed: July 6, 2012
    Publication date: October 2, 2014
    Applicant: Biogen Idec Hemophilia inc.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron Mckinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20140248287
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: January 30, 2014
    Publication date: September 4, 2014
    Applicants: SYNTONIX PHARMACEUTICALS, INC., DYAX CORP.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Fc receptor binding proteins
    Patent number: 8815246
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: August 26, 2014
    Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron K. Sato, Malini Viswanathan
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20130274194
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: March 11, 2013
    Publication date: October 17, 2013
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • Factor VIII-Fc Chimeric and Hybrid Polypeptides, and Methods of Use Thereof
    Publication number: 20130108629
    Abstract: The present invention provides methods of administering Factor VIII; methods of administering chimeric and hybrid polypeptides comprising Factor VIII; chimeric and hybrid polypeptides comprising Factor VIII; polynucleotides encoding such chimeric and hybrid polypeptides; cells comprising such polynucleotides; and methods of producing such chimeric and hybrid polypeptides using such cells.
    Type: Application
    Filed: December 6, 2010
    Publication date: May 2, 2013
    Applicant: BIOGEN IDEC HEMOPHILIA INC.
    Inventors: Jennifer A. Dumont, Susan Low, Alan J. Bitonti, Glenn Pierce, Alvin Luk, Haiyan Jiang, Byron McKinney, Matt Ottmer, Jurg Sommer, Karen Nugent, Lian Li, Robert Peters
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20130078262
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: September 14, 2012
    Publication date: March 28, 2013
    Applicant: Dyax Corp.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20130045218
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: August 13, 2012
    Publication date: February 21, 2013
    Applicants: Syntonix Pharmaceuticals, Inc., Dyax Corp.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato, Malini Viswanathan
  • Fc receptor binding proteins
    Patent number: 8273351
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Grant
    Filed: April 24, 2009
    Date of Patent: September 25, 2012
    Assignees: Dyax Corp., Syntonix Pharmaceuticals, Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
  • FC RECEPTOR BINDING PROTEINS
    Publication number: 20090324614
    Abstract: This disclosure provides, inter alia, proteins that bind to FcRn, e.g., immunoglobulins that inhibit FcRn with high affinity and selectivity. The FcRn-binding proteins can be used to treat a variety of disorders including autoimmune disorders.
    Type: Application
    Filed: April 24, 2009
    Publication date: December 31, 2009
    Applicants: Dyax Corp., Syntonix Pharmaceuticals, Inc.
    Inventors: Christopher TenHoor, Arumugam Muruganandam, Robert Charles Ladner, Clive Wood, Alan J. Bitonti, James Stattel, Kevin McDonnell, Liming Liu, Jennifer Dumont, Aaron Sato
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Patent number: 7429595
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4 -diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and —C(O)—.
    Type: Grant
    Filed: October 2, 2003
    Date of Patent: September 30, 2008
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Patent number: 6861524
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines of the formula where Z is selected from the group consisting of —S(O)2—, and —C(O)—.
    Type: Grant
    Filed: October 31, 2001
    Date of Patent: March 1, 2005
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Publication number: 20040248908
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines of the formula 1
    Type: Application
    Filed: October 2, 2003
    Publication date: December 9, 2004
    Applicant: Aventis Pharmaceuticals Inc.
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • 6,9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
    Patent number: 6642231
    Abstract: The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.
    Type: Grant
    Filed: June 24, 2002
    Date of Patent: November 4, 2003
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Jennifer A. Dumont, Alan J. Bitonti, David R. Borcherding, Norton P. Peet, H. Randall Munson, Jr., Patrick W. Shum
  • 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
    Publication number: 20030105098
    Abstract: The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.
    Type: Application
    Filed: June 24, 2002
    Publication date: June 5, 2003
    Inventors: Jennifer A. Dumont, Alan J. Bitonti, David R. Borcherding, Norton P. Peet, H. Randall Munson, Patrick W. Shum
  • Acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and their use as antiproliferative agents
    Publication number: 20030069259
    Abstract: The present invention is directed to acyl and sulfonyl derivatives of 6,9-disubstituted 2-(trans-1,4-diaminocyclohexyl)-purines and methods of using the same as antiproliferative agents or to prevent apoptosis.
    Type: Application
    Filed: October 31, 2001
    Publication date: April 10, 2003
    Inventors: David Borcherding, Jennifer A. Dumont, Norton P. Peet, Paul S. Wright
  • 6, 9-disubstituted 2-[trans-(4-aminocyclohexyl)amino] purines
    Patent number: 6479487
    Abstract: The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or R3R4N—R5- wherein R2 is selected from the group consisting of C9-C12 alkyl, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C1-C4 alkyl, and wherein each C9-C12 alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C1-C4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C1-C8 alkyl; R3 and R4 are selected from the group consisting of hydrogen, C1-C4 alkyl and (CH2)y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: November 12, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Jennifer A. Dumont, Alan J. Bitonti, David R. Borcherding, Norton P. Peet, H. Randall Munson, Jr., Patrick W. Shum
  • 6,9,-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
    Patent number: 6413974
    Abstract: The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or H2N—R3— wherein R2 is selected from the group consisting of C1-C8 alkyl and  wherein Z is selected from the group consisting of phenyl, heterocycle and cycloalkyl, each R4 is independently hydrogen or C1-C4 alkyl, and n is an integer 1-8; wherein each C1-C8 alkyl and Z is optionally substituted with 1 to 3 substituents, which may be the same or different, selected from the group consisting of Ha1, OH, and C1-C4 alkyl; R3 is C1-C8 alkylene; and R1 is selected from the group consisting of cyclopentyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof. In addition, the present invention provides a method of inhibiting cell cycle progression. More specifically, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2.
    Type: Grant
    Filed: February 9, 1999
    Date of Patent: July 2, 2002
    Assignee: Aventis Pharmaceuticals Inc.
    Inventors: Jennifer A. Dumont, Alan J. Bitonti, David R. Borcherding, Norton P. Peet, H. Randall Munson, Jr., Patrick W. Shum